• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

ACT Biotech

edit

ACT Biotech is uniquely positioned to bring innovative therapies to bear in managing cancer, especially in underserved disease sectors where patient need is acute. The Company’s advantages include a seasoned, international leadership team, unmatched expertise in clinical development and commercialization, and an exceptional portfolio of pre-clinical drug candidates. ACT has launched an aggressive, focused development strategy designed to accelerate delivery of therapeutic tools to respond to the needs of cancer patients. The Company’s strength and stability provide unique opportunities for corporate partnerships to help advance its portfolio of promising, validated drug compounds.

Recent Milestones

edit

• 
  ACT Biotech received $500k in Venture Round funding. (10/14/09)
  Posted 1/12/10 at 5:10pm via sec.gov
• 
  ACT Biotech received $11.7M in Series A funding. (3/1/09)
  Posted 1/12/10 at 5:10pm via sec.gov
• 
  ACT Biotech received $6.24M in Series A funding. (9/8/08)
  Posted 1/12/10 at 5:10pm via sec.gov
• 
  ACT Biotech received $6.57M in Series A funding. (5/6/08)
  Posted 6/6/09 at 6:27am via sec.gov
• 
  ACT Biotech added Wolf D. Busse as CEO.
  Posted 6/6/09 at 6:27am
• 
  ACT Biotech added Ali Fattaey as Chief Operating and Scientific Officer.
  Posted 6/6/09 at 6:27am

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/6/09

Sources

1. SEC D (sec.gov) [edit]
2. SEC D Amended (sec.gov) [edit]
3. SEC D Amended (sec.gov) [edit]
4. SEC D (sec.gov) [edit]